McClung HM, Zhao P, Eckardt A, Smith L, Saulnier Sholler G.  YM155 Inhibits Survivin-mediated survival, migration, and tumor growth in neuroblastoma. American Association for Cancer Research Annual Meeting April 2013. Washington, DC.

Samal K, Zhao P, McClung H, Gerner EW, Bachmann AS, Saulnier Sholler G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Advances in Neuroblastoma Research (ANR) annual meeting, June 2012, Toronto, ON.

McClung HM, Zhao P, Smith L, Saulnier Sholler G. YM155 Inhibits survivin-mediated survival, migration, and tumor growth in neuroblastoma. Advances in Neuroblastoma Research (ANR) annual meeting June 2012, Toronto, ON.

Cecilia M, Mendonça F, Newton T, Saulnier Sholler G, and Roberts S.  Side population analysis and gene expression profiling identify Notch pathway genes in neuroblastoma April 2012 AACR Annual Meeting, Chicago, IL

Saulnier Sholler G, Eslin D, Roberts W, Kaplan J, Bergendahl G, Higgins T, Ashikaga T, Lenox S, Silberman S, Ferguson W. Phase I Trial of TPI 287 as a Single Agent and in Combination with Temozolomide (TMZ) in Patients with Refractory or Recurrent Neuroblastoma (NB) or Medulloblastoma (MB)  June 2011 ASCO Annual Meeting, Chicago, IL

Saulnier Sholler G, Kahn J, Ferguson W, Bergendahl G, Currier E, Lenox S, Bond J, Merchant M,  Roberts W, Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna G, Kamen B, Webb C.  A Pilot Trial Testing the Feasibility of using Molecular-Guided Therapy in Patients with Refractory or Recurrent Neuroblastoma. April 2011 AACR [...]

Saulnier Sholler G, Currier E, Bachmann A.  Synergistic inhibition of neuroblastoma tumor development by targeting ornithine decarboxylase and topoisomerase II. June 2010 Advances in Neuroblastoma (ANR), Stockholm, Sweden

Currier E, Illenye S, Libous J, Bond J, Lescault P, Saulnier Sholler G.  Bortezomib and HDAC inhibitor PCI24781 show synergistic activity in neuroblastoma in vitro and in vivo models, inducing ROS and depressing MYCN. June 2010 Advances in Neuroblastoma (ANR), Stockholm, Sweden

Eslin D, Currier E, Illenye S, Bond J, Webb C, Saulnier Sholler G.  An unexpected finding: Genomic profiling of neuroblastoma predicts tamoxifen as a potential therapy and is confirmed in vitro and in vivo. June 2010 Advances in Neuroblastoma (ANR), Stockholm, Sweden

Currier E, Illenye S, Dorf L, Honigberg L, Saulnier Sholler G.  BTK expression is critical in Neuroblastoma Tumor Initiating Cells. June 2010 Advances in Neuroblastoma (ANR), Stockholm, Sweden